Presentation of Results from the MOXIe Part 2 Study, by Dr. David Lynch

Part 2 of MOXIe was an international, multi-center, double-blind, placebo-controlled Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia.

Kidney Effects in the MOXIe Trial: Presentation at ERA-EDTA 2020

Friedreich’s Ataxia (FA) is a rare, progressive, and debilitating genetic disorder with no approved treatments. Kidney function was assessed in patients with Friedreich’s ataxia in Part 2 of MOXIe, a Phase 2 international, multicenter, double-blind, randomized, placebo-controlled study of omaveloxolone in FA.

Data Presentation: Topline Data from Part 2 of the MOXIe Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

Part 2 of MOXIe was a Phase 2 international, multicenter, double-blind, randomized, and placebo-controlled study in patients with Friedreich’s ataxia, a rare, progressive, and debilitating genetic disorder with no approved treatments.